ABLYNX TO PRESENT DATA ON ITS ANTI-IL-6R NANOBODY, DEVELOPED IN PARTNERSHIP WITH ABBVIE, AT THE
GHENT, Belgium, 14 November 2014 – Ablynx [Euronext Brussels: ABLX] today announced that it will present two posters on its novel anti-IL-6R Nanobody®, ALX-0061, at the 2014 American College of Rheumatology (ACR/ARHP) Annual …